Welcome to European Tribune. It's gone a bit quiet around here these days, but it's still going.
Display:
"Leiden" disputes FDA, EMA abundance of caution
"The Ad26.COV2.S vaccine uses a human Ad26-based vector, whereas the ChAdOx1 nCoV-19 vaccine uses a chimpanzee adenovirus-based vector (references S3 and S4)."
by Cat on Sat Apr 17th, 2021 at 04:20:12 PM EST
[ Parent ]
J&J Privately Asked Rival Covid-19 Vaccine Makers to Probe Clotting Risks
AstraZeneca agrees. Pfizer and Moderna decline, their "shots could be tarnished by association," some people say.
by Cat on Sat Apr 17th, 2021 at 05:21:23 PM EST
[ Parent ]
Blood clots as prevalent with Pfizer and Moderna vaccine as with AstraZeneca's: study, 15 April
According to the study, 4 in 1 million people experience cerebral venous thrombosis after getting the Pfizer or Moderna vaccine, versus 5 in 1 million people for the AstraZeneca vaccine. The risk of getting CVT is much higher for those who get COVID-19 -- 39 in a million patients -- than it is for those who get vaccinated.
CVT statistical analysis, January 20, 2020 and March 25, 2021
cohorts:  Pfizer BNT162b2, Moderna mRNA-1273 (N=489,871); AstraZeneca ChAdOx1 nCoV-19 (N=34M), Janssen Ad26.COV2-S (N=N/A)
controls: influenza (N=172,742), COVID-19 (N=513,284)
The risk of being diagnosed with a CVT was significantly higher in the two weeks after COVID-19 compared to influenza or after receiving an mRNA vaccine. The  risk associated  with  COVID-19 was  also  higher than:(a) that currently reported by the EMA following vaccination with the ChAdOx1 nCoV-19 vaccine;(b) the overall incidence observed inthe TriNetX network or (c) the historical incidence of CVT in the USA.
 
by Cat on Mon Apr 19th, 2021 at 09:30:10 PM EST
[ Parent ]

Display:

Occasional Series